MIM
BCLI

MetLife Investment Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

MetLife Investment Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-877
Closed -$223K – 2277
2020
Q3 		$223K Hold
877
– – ﹤0.01% 1800
2020
Q2 		$148K Buy
+877
New +$94.6K ﹤0.01% 2064

Other funds holding BCLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MetLife Investment Management's BCLI Position: Q4 2020 in Review

MetLife Investment Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2020, closing a stake of 877 shares — an estimated $223K sold.

MetLife Investment Management first reported a position in BCLI in Q2 2020 and held it in 2 quarters. The position peaked at $223K in Q3 2020. 90 funds tracked by Wall St. Rank hold BCLI as of Q4 2020.

  • MetLife Investment Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2020 after selling out during the quarter.
  • MetLife Investment Management sold 877 BRAINSTORM CELL THERAPUTC shares in Q4 2020, an estimated $223K.
  • MetLife Investment Management first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 2 quarters.
  • MetLife Investment Management's BRAINSTORM CELL THERAPUTC position peaked at $223K in Q3 2020.
  • 90 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2020.

Based on MetLife Investment Management's 13F filing for Q4 2020, filed 16 Feb 2021.